Trogenix Expands Scientific Advisory Board with Renowned Experts
Trogenix Ltd, a pioneering biotech company focused on innovative cancer therapies, has made significant strides in its mission to advance treatment options for aggressive cancers by appointing two esteemed professionals, Prof Nada Jabado and Prof Burkhard Becher, to its Scientific Advisory Board (SAB).
Meet the New Advisory Board Members
With their extensive expertise and experience, Prof Jabado and Prof Becher will enhance Trogenix's exceptional capabilities in developing targeted cancer treatments. Prof Jabado specializes in pediatric neuro-oncology, while Prof Becher is renowned for his contributions to immunotherapy. Their appointments mark a new chapter for Trogenix as it works to develop innovative solutions for cancer treatment.
Prof Nada Jabado's Impact on Pediatric Neuro-Oncology
Prof Nada Jabado is a distinguished Professor of Pediatrics at McGill University and serves as a pediatric hematologist-oncologist at the Montreal Children’s Hospital. Her groundbreaking research has revolutionized the understanding of pediatric gliomas by identifying histone mutations as critical factors in tumor development. As an Officer of the Order of Canada and a CIHR Tier 1 Canada Research Chair in Pediatric Oncology, her work exemplifies her commitment to advancing cancer care.
Prof Burkhard Becher's Contributions to Immunotherapy
Prof Burkhard Becher holds the position of Professor and Chair at the Institute of Experimental Immunology, University of Zurich. He has authored over 270 publications that delve into the complexities of immune cell function in inflammation, particularly related to cytokine therapy in neuroinflammatory conditions and cancer treatment. His innovative research has earned him recognition as a Highly Cited Researcher since 2018, underscoring his influence in the field.
Future Directions for Trogenix
Steve Pollard, Chief Scientific Officer at Trogenix, expressed enthusiasm for the new appointments, noting, "We are thrilled that Nada Jabado and Burkhard Becher have joined our Scientific Advisory Board. Their groundbreaking work aligns flawlessly with our vision at Trogenix, and we are excited about the invaluable guidance they will provide as we continue to innovate in cancer treatment. Their insights will be critical in leveraging our unique Odysseus platform for new therapeutic applications."
The Odysseus Platform: Pioneering Cancer Therapy
Trogenix utilizes state-of-the-art technologies, combining genomics, oncology, immunotherapy, and gene therapy to devise revolutionary therapies through its Odysseus platform. This innovative approach employs advanced AAV vectors to deliver proprietary Synthetic Super-Enhancers (SSEs) directly to tumor cells, enhancing the body’s immune response to eradicate cancer cells effectively. The platform offers potential cures through transformative 'one-and-done' treatments, with promising results in preclinical glioblastoma studies reflecting its capabilities across various cancer types and therapeutic applications beyond oncology.
Contact Information for Trogenix
For inquiries regarding Trogenix Ltd or its innovative solutions in cancer treatment, please reach out via their email: info@trogenixbio.com or for media and investor relations: trogenix@icrhealthcare.com.
Frequently Asked Questions
1. What is Trogenix focused on?
Trogenix is dedicated to developing innovative cancer therapies through advanced technologies.
2. Who are the new members of Trogenix's Scientific Advisory Board?
Prof Nada Jabado and Prof Burkhard Becher have recently joined Trogenix's Scientific Advisory Board.
3. What expertise does Prof Nada Jabado bring?
Prof Jabado brings extensive knowledge in pediatric neuro-oncology and has made significant contributions to cancer treatment development.
4. What is the significance of the Odysseus platform?
The Odysseus platform allows Trogenix to deliver targeted therapies directly to cancer cells, enhancing immune responses.
5. How can I contact Trogenix for more information?
You can contact Trogenix via email at info@trogenixbio.com for more information regarding their initiatives and research.
